[1] Keettel WC, Pixley E: Diagnostic value of peritoneal washings. Clinical obstetrics and gynecology 1958, 1:592-606.
[2] Keettel WC, Pixley EE, Buchsbaum HJ: Experience with peritoneal cytology in the management of gynecologic malignancies. American journal of obstetrics and gynecology 1974, 120:174-82.
[3] Mutch DG, Prat J: 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecologic oncology 2014, 133:401-4.
[4] Creasman W: Revised FIGO staging for carcinoma of the endometrium. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2009, 105:109.
[5] Singer G, Oldt R, 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M: Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Journal of the National Cancer Institute 2003, 95:484-6.
[6] Zeppernick F, Ardighieri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, Shih Ie M: BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. The American journal of surgical pathology 2014, 38:1603-11.
[7] Fadare O, Mariappan MR, Wang S, Hileeto D, McAlpine J, Rimm DL: The histologic subtype of ovarian tumors affects the detection rate by pelvic washings. Cancer 2004, 102:150-6.
[8] Parwani AV, Chan TY, Ali SZ: Significance of psammoma bodies in serous cavity fluid: a cytopathologic analysis. Cancer 2004, 102:87-91.
[9] Sadeghi S, Ylagan LR: Pelvic washing cytology in serous borderline tumors of the ovary using ThinPrep: are there cytologic clues to detecting tumor cells? Diagnostic cytopathology 2004, 30:313-9.
[10] Shih Ie M, Panuganti PK, Kuo KT, Mao TL, Kuhn E, Jones S, Velculescu VE, Kurman RJ, Wang TL: Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. The American journal of pathology 2011, 178:1442-7.
[11] Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih Ie M: Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. The Journal of pathology 2014, 232:16-22.